Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 189

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 189
---
 to sell. During the years ended December 31, 2024
no impairment losses have been identified.

| i. | Research and development expenses: |

Research and
development expenses are charged to the statement of comprehensive loss as incurred.

In-Process
Research and Development assets, acquired in an asset acquisition (i.e., assets acquired outside a business combination transactions)
that are to be used in a research and development project which are determined not to have an alternative future use are charged to expense
at the acquisition date in accordance with ASC 730, “Research and Development”.

| j. | Severance pay: |

The subsidiary’s
liability for severance pay is subject to Section 14 of Israel’s the Severance Compensation Act, 1963 (“Section 14”),
pursuant to which all Subsidiary’s employees are included under Section 14, and are entitled only to monthly deposits, at a rate
of 8.33% of their monthly salary, made in the employee’s name with insurance companies. Under Israeli employment law, payments in
accordance with Section 14 release the subsidiary from any future severance payments in respect of those employees. The Company has made
all of the required payments as of December 31, 2024.

The fund is
made available to the employee at the time the employer-employee relationship is terminated, regardless of cause of termination.

The severance
pay liabilities and deposits under Section 14 are not reflected in the consolidated balance sheets as the severance pay risks have been
irrevocably transferred to the severance funds.

Severance expenses
for the years ended December 31, 2024 amounted to $16.

| k. | Income taxes: |

The Company
accounts for income taxes in accordance with ASC No. 740, “Income Taxes”, (“ASC 740”) which prescribes the use
of the liability method whereby deferred tax asset and liability account balances are determined based on differences between financial
reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse.

The Company
provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2024
a full valuation allowance was provided by the Company.

ASC 740 contains
a two-step approach to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the